Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 27.8% during mid-day trading on Saturday . The company traded as high as C$0.12 and last traded at C$0.12. 335,071 shares changed hands during trading, a decline of 31% from the average session volume of 486,759 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Performance
The company has a market cap of C$16.76 million, a PE ratio of -3.35 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The business has a fifty day moving average of C$0.10 and a 200-day moving average of C$0.14.
Insider Activity at Hemostemix
In other Hemostemix news, Director Peter Alan Lacey purchased 200,000 shares of Hemostemix stock in a transaction that occurred on Thursday, March 6th. The shares were bought at an average price of C$0.15 per share, for a total transaction of C$30,000.00. 10.43% of the stock is owned by company insiders.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet
- Best Stocks Under $5.00
- e.l.f. Gets Back on the Shelf! It’s Not Too Late to Buy In!
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
